U.S., March 1 -- ClinicalTrials.gov registry received information related to the study (NCT06852820) titled '68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)' on Feb. 25.
Brief Summary: The purpose of this study is to look at the effects (good and bad) of a drug called 177Lu-PSMA-617 (also known as the study drug) when given to participants who have prostate specific membrane antigen (PSMA) positive liver cancer.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Liver Cancer
Hepatocellular Carcinoma
Metastatic Liver Cancer
Intervention:
DRUG: Lu-PSMA-617
Given IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Melissa Lumish
Information provided by (Responsible Party): Meli...